Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly

Lay Gan, Shivakumar Chitturi, Geoffrey C Farrell, Lay Gan, Shivakumar Chitturi, Geoffrey C Farrell

Abstract

Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis associated with metabolic abnormalities such as overweight/central obesity, insulin resistance, type 2 diabetes (T2D), and dyslipidemia. NAFLD is becoming the most common liver disease in contemporary society, with the highest prevalence in those over 60 years. NAFLD pathology ranges from simple steatosis to a necroinflammatory fibrosing disorder called steatohepatitis (SH), the latter associated with high risk of developing cirrhosis, often occuring in the seventh to ninth decades of life. While the main health implications of NAFLD are increased risk of developing T2D, cardiovascular diseases, and common cancers, there is substantantially increased standardized mortality, and deaths from decompensated cirrhosis and hepatocellular carcinoma (HCC). Little is known about the interactive effects of ageing and NAFLD, with most studies focusing on the younger population. This paper summarises the epidemiology, pathogenesis, and clinical course of NAFLD, with particular attention to persons over age 60 years. An approach to the management of NASH and its complications in the elderly, will also be presented here.

Figures

Figure 1
Figure 1
Mechanism of hepatic steatosis, adapted from Larter et al. 2010 [12], showing also interactions between adipose tissue in differing sites with liver in the development of insulin resistance (IR). FFA: free fatty acids; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue; TG: triglyceride.

References

    1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55(7):434–438.
    1. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Seminars in Liver Disease. 2008;28(4):370–379.
    1. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Current Opinion in Lipidology. 2008;19(3):295–300.
    1. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clinics in Liver Disease. 2009;13(4):511–531.
    1. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. Journal of Gastroenterology. 2011;46(supplement 1):63–69.
    1. Patton HM, Lavine JE, van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135(6):1961–1971.
    1. Frith J, Newton JL. Liver disease in older women. Maturitas. 2010;65(3):210–214.
    1. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) Journal of the American Medical Association. 2001;285(19):2486–2497.
    1. IDF. The IDF consensus worldwide definition of the metabolic syndrome. Metabolic Syndrome. 2007:1–16.
    1. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver International. 2007;27(4):423–433.
    1. Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews. 2010;11(6):430–445.
    1. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. Journal of Gastroenterology and Hepatology. 2010;25(4):672–690.
    1. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. Journal of Gastroenterology and Hepatology. 2005;20(12):1825–1832.
    1. Hsiao PJ, Kuo KK, Shin SJ, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. Journal of Gastroenterology and Hepatology. 2007;22(12):2118–2123.
    1. Wasada T, Kasahara T, Wada J, et al. Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity. Metabolism. 2008;57(7):980–985.
    1. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Seminars in Liver Disease. 2001;21(1):27–41.
    1. Farrell GC. The liver and the waistline: fifty years of growth. Journal of Gastroenterology and Hepatology. 2009;24:S105–S118.
    1. Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K. Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Internal Medicine. 2009;48(10):739–746.
    1. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286–1292.
    1. Yoneda M, Nozaki Y, Endo H, et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Digestive Diseases and Sciences. 2010;55(3):808–814.
    1. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Seminars in Liver Disease. 2004;24(4):349–362.
    1. Wong VW, Chan HLY. Transient elastography. Journal of Gastroenterology and Hepatology. 2010;25(11):1726–1731.
    1. Wong VWS, Vergniol J, Wong GLH, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–462.
    1. de Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients. Liver International. 2010;30(7):1043–1048.
    1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in Liver Disease. 2008;28(4):339–350.
    1. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Canadian Medical Association Journal. 2005;172(7):899–905.
    1. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–131.
    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–1395.
    1. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? Journal of Gastroenterology and Hepatology. 2007;22(6):788–793.
    1. Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. Journal of Gastroenterology and Hepatology. 2011;26(1):153–162.
    1. Younossi Z, Stepanova M, Afendy M, et al. The changing face of chronic liver disease (CLD) in the United States: the rising epidemic of non-alcoholic fatty liver disease (NAFLD) Journal of Hepatology. 2011;54(S1):p. S8.
    1. Tominaga K, Fujimoto E, Suzuki K, Hayashi M, Ichikawa M, Inaba Y. Prevalence of non-alcoholic fatty liver disease in children and relationship to metabolic syndrome, insulin resistance, and waist circumference. Environmental Health and Preventive Medicine. 2009;14(2):142–149.
    1. Tsuruta G, Tanaka N, Hongo M, et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. Journal of Gastroenterology. 2010;45(6):666–672.
    1. Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease—a common and benign finding in octogenarian patients. Liver International. 2004;24(6):588–594.
    1. Dahshan A, Chalmers LJ, Tolia V. Nonalcoholic fatty liver disease in children. Therapy. 2009;6(1):83–91.
    1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. Journal of Hepatology. 2009;50(1):204–210.
    1. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):607–613.
    1. de Bruyn G, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Medical Informatics and Decision Making. 2001;1:e1–e11.
    1. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. European Journal of Gastroenterology and Hepatology. 2004;16(11):1087–1093.
    1. Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology. 2006;40(8):745–752.
    1. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. Journal of Gastroenterology and Hepatology. 2007;22(5):663–668.
    1. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. Journal of Gastroenterology and Hepatology. 2010;25(2):352–356.
    1. Frith J, Jones D, Newton JL. Chronic liver disease in an ageing population. Age and Ageing. 2009;38(1):11–18.
    1. Schmucker DL. Aging and the liver: an update. The Journals of Gerontology Series A. 1998;53(5):B315–B320.
    1. Mentha G, Huber O, Robert J, Klopfenstein C, Egeli R, Rohner A. Elective hepatic resection in the elderly. British Journal of Surgery. 1992;79(6):557–559.
    1. Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional fat distribution. Ageing Research Reviews. 2009;8(4):339–348.
    1. Tran TT, Yamamoto Y, Gesta S, Kahn CR. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metabolism. 2008;7(5):410–420.
    1. Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology. 2010;52(5):1543–1552.
    1. Churilla JR, Fitzhugh EC, Thompson DL. The metabolic syndrome: how definition impacts the prevalence and risk in U.S. adults: 1999–2004 NHANES. Metabolic Syndrome and Related Disorders. 2007;5(4):331–341.
    1. Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Current Hypertension Reports. 2009;11(2):150–155.
    1. Liu CC, Hung CL, Shih SC, et al. Age-related differences in the clinical presentation, associated metabolic abnormality, and estimated cardiovascular risks from nonalcoholic fatty liver disease: a cross-sectional study from health evaluation center in Taiwan. International Journal of Gerontology. 2010;4(4):184–191.
    1. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Japanese Journal of Medicine. 1988;27(2):142–149.
    1. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11(1):74–80.
    1. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. American Journal of Gastroenterology. 2003;98(9):2042–2047.
    1. Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820–826.
    1. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. Journal of Hepatology. 2005;42(1):132–138.
    1. Adams LA, Lymp JF, Sauver JS, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–121.
    1. Day CP, James OFW. Steatohepatitis: a tale of two “Hits”? Gastroenterology. 1998;114(4):842–845.
    1. Berson A, De Beco V, Lettéron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114(4):764–774.
    1. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. American Journal of Physiology. 2011;300(5):G697–G702.
    1. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clinics in Liver Disease. 2009;13(4):565–580.
    1. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Seminars in Liver Disease. 2008;28(4):360–369.
    1. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(5):2498–2502.
    1. Hellemans KH, Hannaert JC, Denys B, et al. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARα-dependent stearoyl-coenzyme a desaturase. PLoS One. 2009;4(9) Article ID e7266.
    1. Morgan NG. Fatty acids and β-cell toxicity. Current Opinion in Clinical Nutrition and Metabolic Care. 2009;12(2):117–122.
    1. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774–788.
    1. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2):S99–S112.
    1. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation. 2005;115(5):1343–1351.
    1. Shiota G. Adiponectin as a therapeutic target of non-alcoholic steatohepatitis. Hepatology Research. 2009;39(10):951–953.
    1. Park BJ, Kim YJ, Kim DH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. Journal of Gastroenterology and Hepatology. 2008;23(6):900–907.
    1. Cheung O, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology. 2007;46(4):1091–1100.
    1. Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. Journal of Biological Chemistry. 2003;278(4):2461–2468.
    1. Lumeng CN, Delproposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes. 2008;57(12):3239–3246.
    1. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. Journal of Gastroenterology. 2008;43(11):811–822.
    1. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–873.
    1. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. Journal of Hepatology. 2008;49(4):608–612.
    1. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterology and Hepatology. 2009;7(2):234–238.
    1. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clinics in Liver Disease. 2009;13(4):545–563.
    1. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.
    1. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18—the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacology and Therapeutics. 2009;30(11-12):1103–1109.
    1. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anatomical Record. 2008;291(6):684–692.
    1. Nakamura Y, Sekikawa A, Kadowaki T, et al. Visceral and subcutaneous adiposity and adiponectin in middle-aged Japanese men: the ERA JUMP study. Obesity. 2009;17(6):1269–1273.
    1. Chitturi S, Wong VWS, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. Journal of Gastroenterology and Hepatology. 2011;26(1):163–172.
    1. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420–427.
    1. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356–1362.
    1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–923.
    1. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100.
    1. García-Monzón C, Martín-Pérez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated obesity. Journal of Hepatology. 2000;33(5):716–724.
    1. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118(6):1117–1123.
    1. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Human Pathology. 2004;35(2):196–199.
    1. Miyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver International. 2008;28(4):519–524.
    1. Bouneva I, Kirby DF. Management of nonalcoholic fatty liver disease: weight control. Clinics in Liver Disease. 2004;8(3):693–713.
    1. Targher G, Bellis A, Fornengo P, et al. Prevention and treatment of nonalcoholic fatty liver disease. Digestive and Liver Disease. 2010;42(5):331–340.
    1. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. The New England Journal of Medicine. 2011;364(13):1218–1229.
    1. Larson-Meyer DE, Heilbronn LK, Redman LM, et al. Effect of calorie restriction with or without exercise on insulin sensitivity, β-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care. 2006;29(6):1337–1344.
    1. Stewart KJ, Bacher AC, Turner K, et al. Exercise and risk factors associated with metabolic syndrome in older adults. American Journal of Preventive Medicine. 2005;28(1):9–18.
    1. Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Seminars in Liver Disease. 2008;28(4):427–433.
    1. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Journal of Hepatology. 1997;27(1):103–107.
    1. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009;17(12):2162–2168.
    1. Chitturi S. Review: treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology. 2008;1(3):173–189.
    1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. The Lancet. 2001;358(9285):893–894.
    1. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2004;19(5):537–544.
    1. Nair S, Diehl AM, Wiseman M, Farr GH, Jr., Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Alimentary Pharmacology and Therapeutics. 2004;20(1):23–28.
    1. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Medical Journal of Australia. 2004;180(2):53–54.
    1. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. 2007;(1):26 pages. Article ID CD005166.
    1. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. American Journal of Gastroenterology. 2001;96(2):519–525.
    1. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology. 2003;38(4):1008–1017.
    1. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39(1):188–196.
    1. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2004;2(12):1107–1115.
    1. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010;51(2):445–453.
    1. Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Alimentary Pharmacology and Therapeutics. 2005;22(10):897–905.
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine. 2007;356(24):2457–2471.
    1. Hopper I. Cardiac effects of non-cardiac drugs. Australian Prescriber. 2011;34(2):52–54.
    1. DeMaria EJ. Bariatric surgery for morbid obesity. The New England Journal of Medicine. 2007;356(21):2176–2183.
    1. Solomon CG, Dluhy RG. Bariatric surgery—quick fix or long-term solution? The New England Journal of Medicine. 2004;351(26):2751–2753.
    1. Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351(26):2683–2693.
    1. O’Brien PE, Dixon JB, Brown W, et al. The laparoscopic adjustable gastric band (Lap-Band®): a prospective study of medium-term effects on weight, health and quality of life. Obesity Surgery. 2002;12(5):652–660.
    1. O'Brien PE. Bariatric surgery: mechanisms, indications and outcomes. Journal of Gastroenterology and Hepatology. 2010;25(8):1358–1365.
    1. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135(1):48–58.
    1. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647–1654.
    1. Varela JE, Wilson SE, Nguyen NT. Outcomes of bariatric surgery in the elderly. American Surgeon. 2006;72(10):865–869.
    1. Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clinics in Liver Disease. 2009;13(4):621–630.
    1. Bromley PN, Hilmi I, Tan KC, Williams R, Potter D. Orthotopic liver transplantation in patients over 60 years old. Transplantation. 1994;58(7):800–803.
    1. Garcia CE, Garcia RFL, Mayer AD, Neuberger J. Liver transplantation in patients over sixty years of age. Transplantation. 2001;72(4):679–684.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi